MAP Kinase Inhibitor Set II

Contains 5 mg of PD 98059 (Cat. No. 513000), 1 mg each of SB 203580 (Cat. No. 559389), and U0126 (Cat. No. 662005), and 1 mg of the negative control, SB 202474 (Cat. No. 559387).

The Mitogen-activated protein kinases (MAP Kinases) are a group of protein serine/threonine kinases that are activated in response to a variety of extracellular stimuli and mediate signal transduction from the cell surface to the nucleus. MAP kinases, in combination with several other signaling pathways can differentially alter phosphorylation status of the transcription factors that is unique to a given signal from outside the cell. A controlled regulation of these cascades is involved in cell proliferation and differentiation, whereas an unregulated activation of these MAP kinases can result in oncogenesis. Three major types of MAP kinase cascades have been reported in mammalian cells that respond synergistically to different upstream signals. They are ERK1/ERK2 MAP kinases, the JNK/SAPK (c-Jun kinase/stress activated protein kinase), and the p38 kinase.



The Calbiochem MAP Kinase Inhibitor Set II contains 4 inhibitors with different MAP Kinase specificities for your convenience.

Packaged under inert gas

Toxicity: Standard Handling (A)

Following reconstitution, aliquot and freeze

(-20°C).

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany